The number of patients eligible for radioligand therapy (RLT) in the European Union is projected to increase tenfold by 2035, rising from an estimated 10,700–13,200 in 2025 to as many as 182,600, according to research published in The Lancet Regional Health—Europe. This surge in demand for targeted cancer treatments necessitates significant expansion of clinical infrastructure, workforce training, and healthcare capacity across member states.
Why is radioligand therapy demand expected to grow?
Radioligand therapies function by delivering radiation directly to malignant cells, sparing surrounding healthy tissue. According to the study by the WifOR Institute, this growth is driven by the expansion of RLT applications to a wider array of cancer types and the use of these treatments in earlier stages of disease progression. As clinical trials validate these therapies for broader patient populations, the current infrastructure—which is designed for smaller, highly specialized patient groups—will face significant pressure to scale up operations.
Unlike traditional external beam radiation, radioligand therapy uses a radioactive isotope linked to a molecule that seeks out specific tumor markers. This precision is why it is increasingly preferred for complex oncological cases.
What infrastructure challenges do healthcare systems face?
Scaling up RLT delivery is not simply a matter of purchasing equipment; it requires a complex logistical overhaul. Dr. Diego Hernandez, a senior researcher at the WifOR Institute, states that healthcare systems must prioritize obtaining new licenses, training specialized medical staff, and integrating these therapies into standard clinical workflows. The modeling conducted for Germany, France, Italy, and Spain indicates that without proactive, long-term planning, the capacity to deliver these treatments could fall short of the rising patient demand.
How can hospitals prepare for this shift?
Long-term planning remains the primary tool for mitigating future capacity bottlenecks. Dr. Malina Müller, Head of Health Economics at WifOR, emphasizes that early investment in capacity is essential to ensure that innovations in cancer care reach patients effectively. For hospitals, this involves:
- Workforce Development: Creating training pipelines for radiochemists, nuclear medicine physicians, and specialized oncology nurses.
- Supply Chain Security: Securing reliable access to radioisotopes, which often have short half-lives and require precise logistics.
- Regulatory Alignment: Updating hospital licensing to handle higher volumes of radioactive materials safely.
Administrators should look toward the “hub-and-spoke” model, where centralized, high-capacity centers handle the complex preparation of radioligands, while regional clinics manage administration and patient monitoring.
Frequently Asked Questions
What is radioligand therapy?
It is a targeted cancer treatment that uses a radioactive substance attached to a targeting molecule to destroy tumor cells while minimizing damage to healthy tissues.
Why does the study highlight the EU-27?
The study specifically modeled the EU-27 to provide a standardized view of how healthcare systems across Europe must prepare for the expected influx of eligible patients over the next decade.
How does this therapy differ from chemotherapy?
Chemotherapy typically affects cells throughout the body, whereas radioligand therapy is designed to home in on specific markers found on the surface of cancer cells.
Are you a healthcare professional or policy expert interested in the future of oncology? Subscribe to our newsletter for the latest updates on medical infrastructure and clinical innovations. Join the conversation below by sharing your thoughts on how your local health system is adapting to new cancer therapies.
